Drugs.com - FDA MedWatch Alerts

Drug Safety Communication: Ocaliva (obeticholic acid) - Serious Liver Injury Being Observed in Patients without Cirrhosis

Audience: Gastroenterology, Hepatology, Patient, Health Care Professional, Pharmacy ISSUE: The FDA identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did...

Apr 26, 2025 - 14:23
 0
Drug Safety Communication: Ocaliva (obeticholic acid) - Serious Liver Injury Being Observed in Patients without Cirrhosis
Audience: Gastroenterology, Hepatology, Patient, Health Care Professional, Pharmacy ISSUE: The FDA identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did...
Read More

Tags:

Previous Article

Buy-herbal.com Issues Voluntary Nationwide Recall of Nhan Sam Tuyet Lien Truy Ph...

Next Article

FDA Investigating Serious Risk of Hematologic Malignancy Following Skysona (eliv...

Related Posts

Veata LLC Issues Voluntary Nationwide Recall of Endurance Pro Capsules Due to the Potential Presence of Undeclared Sildenafil

Veata LLC Issues Voluntary Nationwide Recall of Enduran...

Apr 26, 2025  0

FDA Advises Consumers Not to Inhale Nitrous Oxide Products

FDA Advises Consumers Not to Inhale Nitrous Oxide Products

Apr 26, 2025  0

FDA Adds Boxed Warning to Veozah (fezolinetant) to Highlight the Known Risk of Rare But Serious Liver Injury

FDA Adds Boxed Warning to Veozah (fezolinetant) to High...

Apr 26, 2025  0